SEI Investments’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-62,946
| Closed | -$2.11M | – | 3392 |
|
|
2026
Q1 | $2.11M | Sell |
62,946
-4,384
| -7% | -$172K | ﹤0.01% | 1984 |
|
|
2025
Q4 | $3.12M | Sell |
67,330
-46,503
| -41% | -$2.55M | ﹤0.01% | 1630 |
|
|
2025
Q3 | $7.7M | Buy |
113,833
+81,091
| +248% | +$6.01M | 0.01% | 1118 |
|
|
2025
Q2 | $2.74M | Buy |
32,742
+15,964
| +95% | +$1.19M | ﹤0.01% | 1525 |
|
|
2025
Q1 | $1.2M | Buy |
16,778
+334
| +2% | +$16.3K | ﹤0.01% | 1837 |
|
|
2024
Q4 | $739K | Buy |
16,444
+5,258
| +47% | +$272K | ﹤0.01% | 2052 |
|
|
2024
Q3 | $565K | Buy |
11,186
+4,626
| +71% | +$221K | ﹤0.01% | 2140 |
|
|
2024
Q2 | $268K | Sell |
6,560
-6,017
| -48% | -$255K | ﹤0.01% | 2380 |
|
|
2024
Q1 | $538K | Buy |
12,577
+2,264
| +22% | +$102K | ﹤0.01% | 2086 |
|
|
2023
Q4 | $415K | Sell |
10,313
-3,258
| -24% | -$92.7K | ﹤0.01% | 2185 |
|
|
2023
Q3 | $400K | Buy |
+13,571
| New | +$82.1K | ﹤0.01% | 2201 |
|
SEI Investments's SLNO Position: Q2 2026 in Review
SEI Investments sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 62,946 shares — an estimated $2.11M sold.
SEI Investments first reported a position in SLNO in Q3 2023 and held it in 11 quarters. The position peaked at $7.7M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- SEI Investments reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- SEI Investments sold 62,946 Soleno Therapeutics shares in Q2 2026, an estimated $2.11M.
- SEI Investments first reported a position in Soleno Therapeutics in Q3 2023 and held it in 11 quarters.
- SEI Investments's Soleno Therapeutics position peaked at $7.7M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.